8:45am ET
Investing
Mitsui Sumitomo Continues to Build WR Berkley Stake
W.R. Berkley and Navan have just seen some huge insider purchases. have seen some huge insider purchases, and there were some other notable insider purchases as well.
Companies
/Healthcare
Zentalis Pharmaceuticals Inc
$2.06
▲ $0.08 (+4.04%) today
Markets closed · 7:49pm ET
ZNTL at a Glance
Valuation
- Market cap
- $194.3M
Profitability
- Revenue (TTM)
- $26.9M
- EPS (TTM)
- $-1.96
Price
- 52-week range
- $1 – $7
- Street target
- $7.44
Earnings
- Next report
- Nov 9, 2026
Headquartered in San Diego, CA Fiscal year ends December NASDAQ: ZNTL zentalis.com
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Inc is a New York-based biopharmaceutical company focused on developing innovative small molecule treatments for cancer. With a robust pipeline, including ZN-c3 for various solid tumors and hematological malignancies, and ZN-d5 for blood-related disorders, Zentalis is at the forefront of cancer therapy research. Their work spans multiple clinical trial stages, targeting conditions like ovarian, colorectal, and pancreatic cancers. Collaborating with industry giants like Pfizer and GlaxoSmithKline, Zentalis is committed to advancing cancer treatment options through scientific discovery and strategic partnerships.
Frequently Asked Questions
What does Zentalis Pharmaceuticals do?
Zentalis Pharmaceuticals Inc is a New York-based biopharmaceutical company focused on developing innovative small molecule treatments for cancer.
What is the ZNTL stock price target?
The Wall Street consensus 12-month price target for ZNTL is $7.44.